POSTER PRESENTATION



Open Access

Development of novel vaccine candidates and challenge models for *Plasmodium vivax*

Eduardo Alves^{1*}, Ahmed Salman^{1,2}, Chris Janse², Shahid Khan², Adrian Hill¹, Arturo Reyes-Sandoval¹

From Challanges in malaria research: Core science and innovation Oxford, UK. 22-24 September 2014

Plasmodium vivax is the most widely distributed human malaria parasite in the world and despite nearly 2.5 billion people living at risk, only four vaccines have been assessed in phase I clinical trials and only one has progressed to a phase II trial showing no sterile efficacy. We started to develop new challenge models to assess the efficacy of several new P. vivax pre-erythrocytic vaccine candidates (PVX 091700; PVX 121950; PVX 084090; PVX 099035; PVX_095375; PVX_000975; PVX_003665; PVX_000810) in mice. Our model is based on creating mutant P. berghei (rodent malaria) lines expressing P. vivax antigens through a new method called "Gene Insertion/Marker out" (GIMO). In addition, we are cloning the P. vivax pre-erythrocytic vaccine candidates in recombinant chimpanzee adenovirus (ChAd) and modified vaccine Ankara (MVA) vectors. Upon generation of transgenic parasites and recombinant viruses, a faster assessment to determinate the efficacy of all new P. vivax vaccine candidates can be achieved by using prime/boost immunization regimens followed by a challenge with corresponding transgenic chimera parasites.

Authors' details

 $^1\mbox{Oxford}$ University, Oxford, UK. $^2\mbox{Leiden}$ Malaria Research Group, Leiden, The Netherlands.

Published: 22 September 2014

doi:10.1186/1475-2875-13-S1-P4 Cite this article as: Alves *et al.*: Development of novel vaccine candidates and challenge models for *Plasmodium vivax*. *Malaria Journal* 2014 13(Suppl 1):P4.

¹Oxford University, Oxford, UK

Full list of author information is available at the end of the article



- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

) Bio Med Central

Submit your manuscript at www.biomedcentral.com/submit



© 2014 Alves et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.